FDA lifts clin­i­cal hold on Mus­tang Bio's lentivi­ral gene ther­a­py, paving the way for quick jump in­to piv­otal tri­al

Things were look­ing good for Mus­tang Bio’s MB-107 gene ther­a­py pro­gram. By ear­ly Sep­tem­ber, it had nabbed both rare pe­di­atric dis­ease and or­phan drug des­ig­na­tions, adding to the re­gen­er­a­tive med­i­cine ad­vanced ther­a­py des­ig­na­tion it al­ready scored at the FDA. It all bod­ed well for the piv­otal tri­al they were look­ing to start in new­ly di­ag­nosed in­fants with X-linked se­vere com­bined im­mun­od­e­fi­cien­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER